NCT07471789 2026-03-13
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Gyala Therapeutics
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT06514794 2026-01-05
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
Phase 2 Recruiting
NCT07075328 2025-11-21
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Otsuka Medical Devices Co., Ltd. Japan
Phase 1/2 Recruiting
NCT06035497 2025-05-14
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06462365 2025-04-15
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Tr1X, Inc.
Phase 1 Recruiting
NCT06909474 2025-04-03
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT06136364 2023-11-18
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Hebei Senlang Biotechnology Inc., Ltd.
Phase 1 Recruiting
NCT05626400 2022-11-25
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Recruiting